Literature DB >> 25660262

Must new drugs be superior to those already available? The role of noninferiority clinical trials.

J Rick Turner1, Todd A Durham.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25660262      PMCID： PMC8031872          DOI： 10.1111/jch.12489

Source DB:  PubMed          Journal:  J Clin Hypertens (Greenwich)        ISSN： 1524-6175            Impact factor:   3.738


× No keyword cloud information.
  7 in total

1.  Benidipine has effects similar to losartan on the central blood pressure and arterial stiffness in mild to moderate essential hypertension.

Authors:  Sang-Hyun Ihm; Hui-Kyung Jeon; Shung Chull Chae; Do-Sun Lim; Kee-Sik Kim; Dong-Ju Choi; Jong-Won Ha; Dong-Soo Kim; Kye Hun Kim; Myeong-Chan Cho; Sang Hong Baek
Journal:  Chin Med J (Engl)       Date:  2013       Impact factor: 2.628

2.  The 50th anniversary of the Kefauver-Harris Amendments: efficacy assessment and the randomized clinical trial.

Authors:  J Rick Turner
Journal:  J Clin Hypertens (Greenwich)       Date:  2012-10-03       Impact factor: 3.738

3.  Challenge for hypertension prevention and control worldwide: the time for action.

Authors:  Daniel Lemogoum
Journal:  J Clin Hypertens (Greenwich)       Date:  2014-07-24       Impact factor: 3.738

4.  High blood pressure: why prevention and control are urgent and important: a 2014 fact sheet from the World Hypertension League and the International Society of Hypertension.

Authors:  Norm R C Campbell; Daniel T Lackland; Mark L Niebylski
Journal:  J Clin Hypertens (Greenwich)       Date:  2014-07-17       Impact factor: 3.738

5.  Comparison of efficacy and safety between bisoprolol transdermal patch (TY-0201) and bisoprolol fumarate oral formulation in Japanese patients with grade I or II essential hypertension: randomized, double-blind, placebo-controlled study.

Authors:  Hiroaki Matsuoka; Iwao Kuwajima; Kazuyuki Shimada; Hideo Mitamura; Takao Saruta
Journal:  J Clin Hypertens (Greenwich)       Date:  2013-10-09       Impact factor: 3.738

6.  Zofenopril plus hydrochlorothiazide and irbesartan plus hydrochlorothiazide in previously treated and uncontrolled diabetic and non-diabetic essential hypertensive patients.

Authors:  Enrico Agabiti-Rosei; Athanasios Manolis; Dario Zava; Stefano Omboni
Journal:  Adv Ther       Date:  2014-01-11       Impact factor: 3.845

7.  The fixed-dose combination of olmesartan/amlodipine was superior in central aortic blood pressure reduction compared with perindopril/amlodipine: a randomized, double-blind trial in patients with hypertension.

Authors:  Luis Ruilope; Angie Schaefer
Journal:  Adv Ther       Date:  2013-11-30       Impact factor: 3.845
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.